- Home
- IMCR vs STBA Comparison
IMCR vs STBA Comparison
Compare IMCR & STBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMCR | STBA |
|---|---|---|
| Founded | 2008 | 1902 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | IMCR | STBA |
|---|---|---|
| Price | $28.59 | $44.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 6 |
| Target Price | ★ $66.33 | $43.00 |
| AVG Volume (30 Days) | ★ 369.3K | 202.3K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.29% |
| EPS Growth | ★ 30.39 | 2.35 |
| EPS | 0.25 | ★ 0.94 |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $10.20 |
| Revenue Next Year | $8.21 | $4.14 |
| P/E Ratio | $118.60 | ★ $47.41 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.47 | $34.01 |
| 52 Week High | $40.71 | $45.17 |
Technical Indicators
Market Signals| Indicator | IMCR | STBA |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 53.44 |
| Support Level | $28.90 | $42.25 |
| Resistance Level | $34.35 | $44.64 |
| Average True Range (ATR) | 1.31 | 0.90 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 35.41 | 59.27 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.